On Thursday, Zoetis Inc (NYSE:ZTS)’s shares declined -0.31% to $48.28.
Zoetis Inc. (ZTS) will host a webcast and conference call at 8:30 a.m. (EDT) on Tuesday, Aug. 4, 2015. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Paul Herendeen will review second quarter 2015 financial results and respond to questions from financial analysts during the call.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals worldwide. The company operates through four segments: the United States; Europe/Africa/Middle East; Canada/Latin America; and Asia/Pacific. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines that are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms.
Goodrich Petroleum Corporation (NYSE:GDP)’s shares dropped -2.38% to $1.64.
Goodrich Petroleum Corporation (GDP) declared that it has commenced completion operations on two of its six drilled but unaccomplished wells in the Tuscaloosa Marine Shale (“TMS”). The B-Nez 43H-1 (70%WI) and B-Nez 43H-2 (74% WI) wells in Tangipahoa Parish are near completion of fracture stimulation, with flow back and initial production predictable within 1 - 2 weeks. The Company presently anticipates concluding the remaining four drilled but unaccomplished TMS wells from mid-July through early September. All six wells, which are located within the Company’s core acreage position of 150,000 net acres, will be accomplished prior to the fall borrowing base redetermination planned for October 2015.
The Company’s full year capital expenditure budget of $90 - 110 million was front-end loaded, with about 46% of the budget at the mid-point of guidance spent in the first quarter, as the Company entered the year with three rigs under contract. The Company presently has zero rigs running with plans to bring a rig back to the TMS in October, with no change to formerly issued guidance. The Company re-affirms second quarter capital expenditure guidance of $10 – 15 million and exited the first quarter with in excess of $100 million of liquidity. The Company maintains the ability to enhance liquidity by pursuing a potential joint venture or sale of its Eagle Ford Shale asset.
Goodrich Petroleum Corporation, an independent oil and natural gas company, engages in the exploration, development, and production of oil and natural gas. The company holds interest in the Tuscaloosa Marine Shale located in southwest Mississippi and southeast Louisiana; the Eagle Ford Shale Trend located in South Texas; and the Haynesville Shale Trend in Northwest Louisiana and East Texas.
At the end of Thursday’s trade, TCF Financial Corporation (NYSE:TCB)‘s shares dipped -2.45% to $16.33.
TCF Inventory Finance, Inc., a partner of TCF National Bank and an indirect partner of TCF Financial Corporation (TCB), and Ariens Company (Ariens) declared recently a definitive agreement to provide inventory financing to more than 1,500 Ariens and Gravely dealers across the United States and Canada. TCFIF will be the exclusive financing provider for its portfolio of lawn and garden equipment.
The Ariens Company portfolio of brands comprises some of the oldest and most respected names in the outdoor power equipment industry. The multi-year planned alliance with TCFIF will enable dealers to stock a wide selection of all Ariens® and Gravely® products counting snow blowers, riding mowers, walk behind mowers, and commercial outdoor power equipment.
TCF Financial Corporation operates as the bank holding company for TCF National Bank that provides various retail and commercial banking products and services. The company’s Lending segment offers retail lending services, counting consumer loans for personal, family, and household purposes, such as home purchases, debt consolidation, and financing of home improvements.
XOMA Corp (NASDAQ:XOMA), ended its Thursday’s trading session with -0.67% loss, and closed at $3372.
XOMA Corp (XOMA) declared XOMA 358, a fully human allosteric monoclonal antibody that reduces both the binding of insulin to its receptor and downstream insulin signaling, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of congenital hyperinsulinism (HI).
Orphan drug designation is granted by the FDA Office of Orphan Products Development (OOPD) to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the United States. The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity, in addition to tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance, and waiver of Prescription Drug User Fee Act (PDUFA) filing fees. The OOPD also works on rare disease issues with the medical and research communities, professional organizations, academia, governmental agencies, industry, and rare disease patient groups.
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company’s lead product candidate comprises gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçet’s disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, in addition to diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
